Ronald N. Germain
Ronald N. Germain received his M.D. and Ph.D. from Harvard University in 1976 Since then he has investigated basic immunobiology, first on the faculty of Harvard Medical School, since 1982 in the Laboratory of Immunology, NIH and beginning in 2012 as Chief of the Laboratory of Systems Biology at NIAID, NIH. He and his colleagues have made key contributions to understanding MHC class II molecule structure-function relationships, the cell biology of antigen processing, and the molecular basis of T cell recognition. More recently, his laboratory has explored the immune system using dynamic and static in situ microscopic methods that his laboratory helped pioneer. He has published more than 300 scholarly research papers and reviews. Among numerous honors, he was elected as an Associate (foreign) member of EMBO (2008), elected to the National Academy of Medicine, National Academy of Sciences USA (2013), received the Meritorious Career Award from the American Association of Immunologists (2015), chosen as NIAID Outstanding Mentor (2016), elected to the National Academy of Sciences (2016) and has been designated an NIH Distinguished Investigator. He has trained more than 70 postdoctoral fellows, many of whom hold senior academic and administrative positions at leading universities and medical schools.
Gwendolyn Binder-Scholl, Ph.D. is the Chief Technology Officer of Adaptimmune, responsible for its research and translational science teams. Her strategic focus is on optimizing the therapeutic potential of Adaptimmune’s product, through late preclinical and translational programs, which are closely integrated with clinical outcomes and emerging data in the field. Gwendolyn’s original training is in viral neuro-immunology at Johns Hopkins University, Baltimore. Since 2002, she has worked in translational research, cell manufacturing, regulatory affairs, clinical development and translational medicine / correlative research in the field of cell and gene therapy, with a research focus in T cell immunotherapy for HIV and oncology. She previously held positions at the University of Pennsylvania as the Director of Translational Research Operations, under Carl June, where she oversaw the opening of 5 new INDs for novel gene therapy products, including CD19-CAR, ZFN, and several TCR engineered T cells. Prior to the University of Pennsylvania, Gwendolyn was the Director of Scientific Affairs at Virxsys Corporation, where she was closely involved in the translational and regulatory aspects of the first human application of a lentiviral vector. She is the founding member of the US arm of Adaptimmune, and serves on the Executive Committee for the company.
Shannon J. Turley
Shannon Turley is a Principal Scientist at Genentech, and the focus of her research team is to establish a deep understanding of stromal cell function in inflammation and cancer. She has over 20 years of research experience in the field of immunology and has published research articles in peer-reviewed journals including Nature, Science, Nature Immunology, Immunity, Science Translational Medicine, Journal of Experimental Medicine, Proceedings of the National Academy of Sciences and many more. She is on the Editorial Board of Journal of Experimental Medicine, Trends in Immunology, Cancer Immunology Research and a permanent member of the TTT Study Section at the National Institutes of Health. Dr. Turley started her laboratory at the Dana Farber Cancer Institute at Harvard Medical School in 2004 where her initial discoveries in stromal immunobiology and cancer immunology were made. Her group has studied antigen presenting cells and stromal cells for over a decade now, and has made several fundamental discoveries regarding the immunoregulatory functions of stromal cells and their role in promoting proper lymphoid tissue architecture, leukocyte trafficking, antigen presentation, immune regulation, peripheral tolerance and facilitating appropriate cell-cell interactions. The group employs transcriptomic, proteomic, genetic, metabolomic and functional analyses as well as dynamic and high resolution, quantitative imaging technologies and more recently has embarked on a major effort to elucidate stromal immunobiologic cascades at the single cell level. In 2014, and after 10 years on the faculty at Harvard Medical School and Dana Farber Cancer Institute, Dr. Turley was recruited to the Department of Cancer Immunology at Genentech as a Principal Scientist and Group Leader to build a stromal immunobiology program with a focus on developing myeloid- and stromal-targeted immunotherapeutics for treating patients with inflammatory diseases and advanced solid tumors.
University of Pennsylvania
Dr. Bruce Levine, Barbara and Edward Netter Professor in Cancer Gene Therapy, is the Founding Director of the Clinical Cell and Vaccine Production Facility (CVPF) in the Department of Pathology and Laboratory Medicine and the Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania. He received a B.A. in Biology from the University of Pennsylvania and a Ph.D. in Immunology and Infectious Diseases from the Johns Hopkins University. The CVPF develops and tests novel cell and gene therapies in clinical trials in patients with hematologic malignancies, solid tumors, HIV infection, and genetic disease. First-in-human trials include the first use of a lentiviral vector, the first infusions of gene edited cells, and the first use of lentivirally-modified cells to treat cancer. Dr. Levine has overseen the production, testing and release of 2,800 cellular products administered to >1,100 patients in clinical trials since 1996. Through these technologies, personalized and enhanced immunity has been engineered. T lymphocytes from HIV+ subjects have been rendered resistant to HIV infection and reinfused. T lymphocytes from cancer patients have been redirected with chimeric antigen receptors (CAR's) to hunt and destroy their malignancies. This therapy, developed by the CVPF and licensed by Novartis, recently became the first FDA approved gene therapy (Kymriah).
Andy Sewell’s research interests have focused around how organisms deal with environmental adversity. He began his career at the University of Liverpool by applying his training in chemistry towards phytoremediation strategies. He then moved to the University of Utah in 1990 to work on gene activation by environmental stress. He returned to Oxford in 1995 to work on the strategies HIV and other viruses use to subvert human T-cell immunity. In 2006 he took up a position in Cardiff as Distinguished Research Professor in the School of Medicine. He continues in Cardiff and is currently a Wellcome Trust Senior Investigator. His research focuses on T-cell antigens and the receptors that recognize them. This takes the Sewell laboratory in many different directions including transplant tolerance, autoimmune disease, immunity to infection and cancer immunotherapy.
Bernd Schröder is the Global Head of Regulatory Affairs at the Teterow site of Miltenyi Biotec GmbH. After graduating from the University of Bonn, where he studied biology with a focus on microbiology and biotechnology, he spent several years at the Research Center Jülich where he completed his PhD on the “Cultivation and characterization of hematopoietic and stromal cells for bone marrow stimulation in a bioreactor“. Before joining Miltenyi Biotec in 2003, he was the Head of R&D Cell Therapy and, from 2002, Head of Production at MainGen Biotechnologie GmbH in Frankfurt, Germany.
Technical University Munich
Martin Hildebrandt is a hematologist and transfusion specialist. He graduated from the Free University Berlin in 1993 and was board certified in Internal Medicine (2002), Hematology and Oncology (2008) and Transfusion Medicine (2016). As coordinator and participant of several EC-funded research projects (ACADEMIC GMP, AGORA, BIOHYBRID, TETRA), he contributed to the definition of an academic position in the development of cell-based and gene therapies in Europe. Prof Hildebrandt has been in charge of Academic GMP facilities in Berlin and Hannover, Germany, before taking over the responsibility for establishing TUMCells, the Interdisciplinary Center for Cellular Therapies at TUM School of Medicine, where he serves as Executive Director and Qualified Person. His focus of regulatory expertise lies with GCP/GMP, ATMP development and manufacture. The major area of research of Martin Hildebrandt is T-cell mediated immunomodulation and Transplant optimisation.
Prof. Hildebrandt is member of the working group on blood-associated infections at the German Federal Ministry of Health, Chair of the Ethics Committee of the State of Berlin, advisor to the German Working Group on Chronic Rare Diseases (ACHSE), and member of several academic consortia and professional societies.
Committee for Advanced Therapies (CAT), European Medicines Agency
Dr. Martina Schüssler-Lenz is currently working as M.D. at the Paul-Ehrlich Institute and is Chair of the Committee for Advanced Therapies. The Committee for Advanced Therapies (CAT) is the European Medicines Agency's (EMA) committee responsible for assessing the quality, safety and efficacy of advanced therapy medicinal products (ATMPs).
Overall, Martina has 30 years of professional experience. She completed her clinical training in Mainz and Berlin (Board Certified Internist), and worked as a postdoctoral fellow in tumor biology and immunology in New York (Memorial Sloan Kettering Cancer Center) and Barcelona (Instituto Municipal de investigacion Medica).
During her 13 years in the pharmaceutical industry (Asta Medica, Baxter Oncology) she held various positions and was responsible for several international clinical drug development projects of anticancer agents
At the Paul-Ehrlich-Institut, the German Federal Agency for Vaccines and Biomedicines, she holds a position as Deputy Head, Section Advanced Therapy Medicinal Products and is responsible for advising companies on drug development issues, assessing clinical trials and reviewing marketing authorisations.
She contributes to the development of guidelines in the ATMP field. Her work has resulted in several (co-)authorships in scientific journals, as for example recently the “Clinical development of CAR-T cells – challenges and opportunities in translating innovative treatment concepts” in EMBO Molecular Medicine (online 1.8.2017 DOI 10.15252/emmm.201607485).
Weill Cornell Medical College
Sandra Demaria, M.D., a native of Turin, Italy, obtained her M.D. from the University of Turin, and then moved to New York City for her post-doctoral training in immunology as a Damon Runyon-Walter Winchell Cancer Research Fund awardee, followed by a residency in anatomic pathology at New York University School of Medicine (NYU SoM). She is currently Professor of Radiation Oncology and Pathology at Weill Cornell Medicine Medical College in New York City. Dr. Demaria is internationally known for her studies demonstrating the synergy of local radiation therapy with different immunotherapeutic agents in pre-clinical models of cancer. She was the first to show that radiotherapy can convert tumors unresponsive to immune checkpoint inhibitors into responsive ones, a finding being translated in several clinical trials at multiple institutions. Her current work is aimed at identifying the molecular mechanisms that regulate ionizing radiation’s ability to generate an in situ tumor vaccine in both preclinical tumor models as well as cancer patients treated in clinical trials testing various combinations of radiation and immunotherapy. She holds leadership positions in national professional societies, including the Society for Immunotherapy of Cancer (SITC) and AACR, and is an elected member of the European Academy for Tumor Immunology (EATI).
German Cancer Research Center (DKFZ)
In 1971, Günter Hämmerling joined the laboratory of Hugh McDevitt at the Stanford University Medical School, USA, to study the function of MHC linked “immune response genes”, resulting in the description of Ia antigens, known today as MHC class II. In 1974 he joined the laboratory of Klaus Rajewsky at the University of Cologne, Germany, where he introduced monoclonal antibodies for the functional analysis of MHC molecules. Since 1979 Günter Hämmerling has held the position of Chairman of the Division of Molecular Immunology at the German Cancer Research Center Heidelberg, Germany, where he concentrated on mechanisms of antigen presentation, peripheral tolerance, and tumor immunology. This work led to the clinically important observation that the degree of T cell infiltration into tumors can be manipulated genetically or by inflammatory mediators, resulting in more efficient elimination of tumors.
He is a member the European Molecular Biology Organization EMBL and served on various Scientific Advisory Boards including the Helmholtz Center for Infection Research HZI, Braunschweig, Germany, the German Center for Rheumatology Research DRFZ, Berlin, Germany, the Association for Immunotherapy of Cancer CIMT, the World Premier Institutes Japan, the Cochin Institute Paris, the Institute Necker Paris. He was co-founder and president of the European Network of Immunology Institutes ENII, and president of the German Society of Immunology DGfI. He also serves on a number of editorial boards of scientific journals. To date, he has authored more than 370 publications in leading scientific journals.
Falk Nimmerjahn was trained in molecular biology, genetics and immunology at the Universities of Bayreuth, Erlangen-Nuremberg, and Munich, where he obtained his PhD. After two years of postdoctoral training at the Helmholtz Centre Munich he joined Prof. Ravetchs’ laboratory in New York in 2004, where he studied how different IgG subclasses mediate their activity in vivo and how IgG glycosylation impacts antibody activity. In 2007 he was appointed as an associate professor at the University Hospital of Erlangen and head of the laboratory of Experimental Immunology and Immunotherapy. In 2010 he became full professor and chairman of the Institute of Genetics at the Friedrich-Alexander University of Erlangen-Nuremberg. His group has several major areas of interest, all focusing on a better understanding of how immunoglobulin G (IgG) antibodies work in mice and humans in vivo. This includes in depth studies on the activity of cytotoxic antibodies and studies deciphering the mechanisms of how self-reactive antibodies (autoantibodies) mediate tissue inflammation and destruction during autoimmune diseases. In addition to using a wide variety of classical inbred mouse models, his group develops novel humanized mouse models allowing to study human antibody activity on the background of an outbred human immune system in vivo.
MD Anderson Cancer Center
Since joining the Department of Melanoma Medical Oncology at MD Anderson Cancer Center in July 2013, Dr. Amaria has worked to establish herself as a clinical and translational researcher. She is the Principle Investigator or Co-Principle Investigator of numerous clinical trials, with the majority being investigator-initiated where she had the key role in design and implementation. Dr. Amaria’s research interests have coalesced around two major subjects; neoadjuvant therapy and translational immunotherapy including adoptive cell therapy in metastatic melanoma. Dr. Amaria has designed and implemented two clinical trials for neoadjuvant therapy in patients with high risk, resectable melanoma. Both of these trials has produced compelling clinical and translational data and provide a framework for standardization of neoadjuvant treatment in advanced stage melanoma. Additionally, Dr. Amaria is currently leading the melanoma adoptive cell therapy program and is responsible for running trials utilizing genetically modified T cells as well as combination therapy with checkpoint inhibition. She is also the co-leader of the Melanoma Biospecimen Collection Team and in this role she oversees collection of serial blood and tumor samples from patients being treated with systemic therapies to help in understanding molecular and immunologic mechanisms of treatment response or failure. Since joining MD Anderson, Dr. Amaria has had the privilege of working with strong mentors including Dr. Patrick Hwu and Dr. Michael Davies, who are leaders in the field of melanoma and translational research. Additionally, Dr. Amaria has established a busy clinical practice and has extensive experience treating melanoma patients on and off clinical trial protocols.
Andrea van Elsas
Andrea van Elsas became Chief Scientific Officer (CSO) in September 2017, following his tenure as Chief Scientific Officer of Aduro Biotech Europe since November 2015. Prior to its acquisition by Aduro in 2015, Dr. Andrea van Elsas co-founded BioNovion and served as Chief Scientific Officer focusing on the development of innovative therapeutic antibodies in the field of immune oncology. From 1999 to 2011, he held numerous positions at Organon in Oss, The Netherlands, and Cambridge, Massachusetts (acquired by Schering-Plough Corporation in 2007 and later by Merck & Co.), and as the Director of Tumor Immunology he ran the immune oncology portfolio including the program that later became known as pembrolizumab. As a postdoctoral researcher from 1997-1999, Andrea worked at the University of California, Berkeley, studying antibodies blocking CTLA-4 for the treatment of cancer and is a co-inventor on the original patents that formed the basis for the development of Yervoy® (ipilimumab), the first checkpoint inhibitor approved in 2011 by the U.S. Food and Drug Administration for the treatment of melanoma.
University of Verona
Dr. Vincenzo Bronte is currently Head of the Immunology Section in the Department of Medicine of Verona University and Head of the U.O.C of Immunology in the Policlinico G. B. Rossi Hospital. He is Full Professor of Immunology at the University of Verona. Dr. Bronte was awarded by the Accademia Nazionale dei Lincei (Rome, Italy) with the International Prize "Francesco De Luca" for scientific Oncology career, and by the Italian Foundation for Cancer Research (FIRC) with the Prize "Guido Venosta" for oncology researchers.
Dr. Bronte’s major achievements has been the definition and characterization of immunoregulatory cells, now called myeloid-derived suppressor cells (MDSCs), whose negative influence on antitumor immunity represents an obstacle to a successful immunotherapy of cancer. Current projects in the laboratory are further exploring the cellular and molecular mechanisms underlying tumor-induced immune dysfunctions, with the attempt to define novel drugs and approaches targeting tumor microenvironment, to be used alone or in combination with either active or passive immunotherapy strategies.
Dr. Bronte is section editor for The Journal of Immunology, associate editor of Frontiers in Immunology and Frontiers in Oncology, editorial board member of the Journal of Translational Medicine and Senior editor for Cancer Immunology Research and cell stress.
University of Toronto
Tania Watts received her B.Sc. and Ph.D. degrees in Biochemistry from the University of Alberta, Canada and conducted post-doctoral work at Stanford University in the laboratory of Professor Harden McConnell where she used supported planar membranes and TIRF microscopy to study T cell-MHC II/peptide interaction. In 1986, Dr. Watts took up a faculty position at the University of Toronto in the Department of Immunology. For more than 20 years, her research has focused on the TNFR superfamily, particularly on the role of TNFR family members in control of viral infection, and the role of TNFRs in lymphocyte and cancer cell survival. Dr. Watts is a past president of the Canadian Society for Immunology (CSI) and in 2016 was the recipient of the CSI Cinader award. Dr. Watts is currently Professor of Immunology at the University of Toronto and director of the Faculty of Medicine Flow cytometry facility. Watts founded and directs the Toronto Human Immunology Network (http://humanimmunology.utoronto.ca), a Federation of clinical immunological societies center of excellence. Watts currently holds the Sanofi Pasteur Chair in Human Immunology at the University of Toronto. Website: http://www.immunology.utoronto.ca/content/tania-watts
National Center for Scientific Research "Demokritos" Athens
Dr. Dimitrios Mastellos is a Senior Researcher at the National Center for Scientific Research ‘Demokritos’ in Athens, Greece. Dimitrios studied biology at the University of Patras, Greece, and earned his PhD in Immunology from the Medical School of the same institution. As a postdoctoral scientist at the University of Pennsylvania, he applied animal models to interrogate the role of complement-triggered pathways in diverse pathophysiological processes and biological milieus. His research in ‘Demokritos’ focuses on how complement modulates innate immune activation, host-pathogen interactions and inflammatory signaling in health and disease.
Cancer Research UK
Dr Nicholas McGranahan completed his undergraduate degree in Natural Sciences, specializing in Evolutionary Genetics, at the University of Bath before pursuing post-graduate studies at University College London at the Centre of Mathematics and Physics in the Life Science and Experimental Biology (CoMPLEX). In 2011, Dr McGranahan joined Professor Charles Swanton’s group at the CR-UK London Research Institute (now the Francis Crick Institute), completing a PhD in Cancer Genomics in 2015.
As a junior group leader within the CRUK Lung Cancer Centre of Excellence, Dr McGranahan’s research interests include using bioinformatics to dissect cancer genome evolution and the mechanisms of drug resistance, intra-tumour heterogeneity and genomic instability. His work involves exploring the evolutionary history of cancers through sequencing multiple regions of individual tumours. In particular, Dr McGranahan’s research has focused on understanding the importance of genome doubling in tumour evolution, as well as exploring the mutational processes shaping the genomes of cancers over space and time. Dr McGranahan has authored over 30 articles in high impact journals, including first author publications in Science, Nature, Cell, New England Journal of Medicine and Cancer Cell.
Jolanda de Vries
I. Jolanda M. de Vries is Professor of Translational Tumour Immunology at the Radboudumc in Nijmegen. She obtained her PhD degree at the University of Utrecht in 1997 and afterwards became a postdoctoral researcher Nijmegen. Jolanda is a researcher who believes in the potential of the immune system to tackle cancer without significant side effects. It is her scientific ambition to translate results from the laboratory as soon as possible to clinical applications.
Jack Pollard leads the Bioinformatics group for Sanofi Oncology. His group contributes targets, biomarkers, and drug combinations into Oncology’s pipeline using a mix of experiment design, mathematics, computation, data management, and consulting skills. He has also developed and executed the translational medicine plans and biomarker strategies for several molecules that have progressed into the clinic. Prior to joining Sanofi while at the ventured backed personalized healthcare company Selventa/Genstruct, he developed biological network reconstruction methods to identify patient stratification biomarkers using knowledge graphs. He has received several Small Business Innovation awards from NIH and is a National Institute of Standards and Technology Advanced Technology Program grant winner. He is an inventor on several patents in biological network reconstruction, semantic integration technologies, and machine learning. Jack holds a doctorate in Biochemistry and Molecular Pharmacology from Harvard Medical School, where he studied the origins of life.
University of Chicago
Melody A. Swartz is a Professor in the Institute for Molecular Engineering at the University of Chicago, where she holds the William B. Ogden Chair and a joint appointment in the Ben May Department for Cancer Research. She holds obtained her BS from Johns Hopkins and PhD from MIT, both in Chemical Engineering. Her PhD focused on lymphatic physiology and biomechanics in the lab of Rakesh Jain, after which she undertook postdoctoral studies in mechanobiology at Brigham & Women’s Hospital in the lab of Jeffrey Drazen. She was an Assistant Professor at Northwestern University in the Department of Biomedical Engineering before moving to the Ecole Polytechnique Fédérale de Lausanne (EPFL), where she was promoted to Full Professor and spent 13 years in the Institute of Bioengineering and the Swiss Institute for Experimental Cancer Research. Trained as a bioengineer, she uses quantitative approaches in immunobiology and physiology, including biotransport and biomechanics, to develop a deeper understanding of how the lymphatic system regulates immunity in homeostasis and disease, particularly in cancer and chronic inflammation. Her lab applies this knowledge to develop novel immunotherapeutic approaches in cancer, including lymph node-targeting vaccine approaches, as well as in vitro model systems that recapitulate relevant features of the 3D, perfused tumor microenvironment.
University Hospital of Cologne
Peter Borchmann is Assistant Medical Director in the Department of Hematology/Oncology at the University Hospital of Cologne. He is head of the lymphoma program in this department and Co-Chairman of the German Hodgkin Study Group (GHSG). His clinical research is based on investigator initiated clinical studies from phase 1 to phase 3. His scientific career is focused on immunotherapy of B-cell malignancies. His group has been selected to conduct the first pivotal CAR T-cell trial in Germany. He is member of different national and international organizations (DGHO; EHA; ASH).
Technical University Munich
Dr. Jan Böttcher is a Junior Group Leader at the Institute of Molecular Immunology and Experimental Oncology, TU Munich. He obtained his PhD in Molecular Biomedicine from the University of Bonn in 2013, where he investigated the regulation of cytotoxic T cell immunity and T cell memory. For his postdoctoral training, Dr. Jan Böttcher joined Caetano Reis e Sousa’s lab at the Francis Crick Institute in London to study dendritic cells in anti-cancer immunity.
In 2018, Dr. Böttcher was awarded funding from the Elite Network of Bavaria to form his independent Junior Research Group at TU Munich. His work focuses on the mechanisms that control immunity to cancer within tumors and their surrounding microenvironment.
MD Anderson Cancer Center
Yared Hailemichael, PhD is a research instructor at MD Anderson Cancer Center. He and his colleagues have made seminal contributions to cancer immunology in defining the regulation of CD8+ cytotoxic T cell tumor localization and tumor killing, leading to a Phase I clinical study of novel vaccine. In his major contribution to cancer immunotherapy, he showed persistent cancer vaccine formulations force tumor-specific T cells sequestration, dysfunction and deletion at the vaccination site, preventing them from trafficking to tumor and cause tumor destruction. Since then he has identified the key immunological mechanism that control cancer vaccine formulation synergy with CTLA-4, PD-(L)1 checkpoint blockade therapy. Currently, as a key researcher on the integrin agonist molecule 7HP349 translational and Phase I Clinical team, he leads the validation of ICAM-1/LFA-1 and VCAM-1/VLA-4 axes as critical to CTLA-4, PD-(L)1 resistance, and reversal of such resistance by 7HP349, which is a small molecule activator of these integrins.
University College London
Dr Martin Pule was the first to describe third generation forms of Chimeric Antigen Receptors (CARs) and described one of the first clinical studied of CARS, which showed efficacy in a solid cancer.
He is the Clinical Senior Lecturer in the Department of Haematology at UCL Cancer Institute, and Honorary Consultant in Haematology at University College Hospital. His Research is focused on many aspects of genetic engineering of T-cells for cancer treatment, with particular focus on CARs.
In 2014 Martin founded Autolus Ltd; a synthetic biology / CAR company which was the largest series A in European biotech. As Chief Scientific Officer, he is overseeing the development of next-generation engineered immune-cell technology.
German Cluster for Individualized Immunointervention (Ci3)
Özlem Türeci is an MD with over 25 years of expertise in cancer research and immune oncology. She is chair and co-initiator of the German Cluster of individualized Immunointervention (CI3). Özlem is one of the scientists behind the Biotech companies Ganymed (now a subsidiary of Astellas) and Biontech. As Chief Executive Officer of Ganymed she led the development of novel mAbs against solid cancers. In Biontech she acts as head of the Scientific and Clinical Advisory Board. Furthermore, she is an executive board member of the Association for Cancer Immunotherapy (CIMT).
Medical School Hannover (MHH)
Viktor Grünwald is an Attending Physician at the Hannover Medical School, Clinic of Haematology, Haemostasis, Oncology, and Stem Cell Transplantation. Professor Grünwald specialises in Internal Medicine, Medical Oncology and Haematology. His main areas of research interest are in renal cell carcinoma, soft tissue sarcomas, head and neck cancers, with an emphasis on the development of molecular and immunotherapies.
Prof Grünwald graduated from the Medical School Hannover in 1998, after which he was appointed as a Private Lecturer in Haematology and Oncology at the same institution. He became professor for Haematology and Oncology at the Medical School Hannover in 2014. Professor Grünwald was appointed to the steering committee for genitourinary (GU) cancers (non-prostate) at the ESMO and ESMO ASIA Congress and is part of scientific committees of the International Kidney Cancer Symposium (EIKCS), German Cancer Congress (DKK) and the German Society for Hematology and Oncology (DGHO). He has co-chaired the Phase 3 Working Group of the Central European Society of Anticancer Drug Research (CESAR) studies group and a former member of the board of the German Medical Oncology studies group (AIO). Prof. Grünwald chairs the AIO Head and Neck (SCCHN) Working Group and within the AIO he is the former spokesman of the Sarcoma (STS) Working Group. Within the German Cancer Society, he chairs the Working Group for renal tumors (RCC) and is co-chair of the interdisciplinary head and neck tumors group. He chairs the ESMO preceptorship on SCCHN and is part of the faculty of the ECCO-AACR-EORTC-ESMO workshop on methods in clinical cancer research. His current trial proposals explore novel concepts in RCC, STS and SCCHN, focusing on translational research and drug development of immunotherapies in these indications.
National Center for Tumor Diseases (NTC)
Guy Ungerechts MD, PhD is a medical oncologist trained in the field of oncolytic viruses at Mayo Clinic, Rochester, USA and at The Ottawa Hospital Research Institute (OHRI), Ottawa, Canada. He is Deputy Director of the Medical Oncology Department at the National Center for Tumor Diseases (NCT), Heidelberg, Germany focused on GI cancers with particular interests in translational medicine and early clinical trials of immuno(viro)therapy.
Since 2008 Guy heads the Virotherapy group at NCT/DKFZ as an independent researcher and coordinates the German Virotherapy Consortium. He has been responsible for the development and conduction of several Phase I/II and III trials with oncolytic viruses derived from different platforms including oncolytic measles virus, vaccinia virus (JX-594), parvovirus H-1 and herpes simplex virus (HSV-1). His group recently demonstrated for the first time that measles virus can be armed with immunomodulatory transgenes encoding for cytokines, immune checkpoint blockade antibodies and bispecific T cell engager (BITEs) for enhanced immunovirotherapy.
Since 2015 he is holding an Ontario Institute for Cancer Research (OICR) sponsored clinician-scientist position in Ottawa, Canada. As a staff medical oncologist, he was member of the GI cancer group at The Ottawa Hospital (TOH) between 2015 and 2017. He is adjunct professor at the University of Ottawa and PI at the OHRI in Dr. John Bell´s research program.